Hepion pharmaceuticals announces adjournment of annual meeting

Edison, n.j., june 25, 2021 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("nash"), today announced that its 2021 annual meeting of stockholders, scheduled for june 25, 2021, has been adjourned due to a lack of quorum. the adjourned meeting will be held at 9:00 a.m. eastern time on friday, july 23, 2021. the record date for determining stockholders eligible to vote on the proposals at the annual meeting remains april 29, 2021. a stockholder may use one of the following simple methods to vote:
HEPA Ratings Summary
HEPA Quant Ranking